drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An allogeneic (off-the-shelf) anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy delivered as a single infusion after lymphodepleting chemotherapy. Gene-engineered T cells express a CAR recognizing CD19 to deplete CD19+ B cells (B-cell aplasia) and reset immunity to reduce pathogenic autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic gene-engineered T cells expressing an anti-CD19 chimeric antigen receptor bind CD19 on B-lineage cells and kill them via T-cell cytotoxicity, causing deep B-cell depletion (B-cell aplasia) and an immune reset that reduces pathogenic autoantibody production.
drug_name
BRL-301
nct_id_drug_ref
NCT05859997